he National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) has contributed biopharmaceutical manufacturing ontologies to The Open Applications Group (OAGi) for further development as an open-source project. Shifting NIIMBL’s ontology work to an open-source process will encourage broader involvement and adoption of common...
The National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) has published “ Vaccine process technology—a decade of progress ” in Biotechnology and Bioengineering . The paper serves as an update to a 2012 review titled “ Vaccine process technology ” authored by NIIMBL Executive Director Barry Buckland and explores...
The National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) is pleased to announce 63 students from 41 academic institutions have been selected to take part in the 2024 NIIMBL eXperience, the largest cohort since the Program’s launch in 2019. Students will participate in one of five NIIMBL eXperience programs hosted by Albany...
The National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) officially launches the Viral Vectors NIIMBL-led Program focused on developing and making broadly available robust, economically viable, shared manufacturing process and analytical platforms for Adeno-Associated Virus (AAV) gene therapy vectors. NIIMBL has committed...
The Advanced Manufacturing National Program Office held its annual Manufacturing USA Network Meeting on May 25 in Washington, DC. There were over 100 participants with representatives from each of the institutes and funding agencies attending nine unique sessions throughout the day.
Dr. Monica Gorman, Special Assistant to the President for...
